🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the fight against superbug strains of the infection, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are increasing globally, with data suggesting in excess of 82 million instances each year. Especially elevated rates are observed in Africa and nations within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The global health body has listed it as a "critical concern". A tracking program showed that the effectiveness of standard treatments like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Clearance

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US FDA in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Experts hope that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in the same week. This medication, which is also used to treat UTIs, was shown in trials to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone represents a major breakthrough in the management of highly resistant gonorrhoea, which until now has been evolving faster than our drug pipeline.”

Testing Outcomes and Worldwide Availability

Based on results published in a major medical journal, the new drug cured more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which involves an injection and a pill. The research involved hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in numerous developing nations.

Clinicians directly involved have voiced optimism. The availability of a easy-to-administer therapy of this kind is described as a "game-changer" for public health efforts. This is considered essential to alleviate the strain of the illness for people and to stop the proliferation of highly drug-resistant gonorrhoea globally.